Figure 2.

Clozapine treatment (a) resulted in a greater reduction in disease than risperidone (b), quetiapine (c), or olanzapine (d) and at doses below the mean human dose as assessed by plasma concentrations (e) and weight gain (f). (a–d) C57BL/6 female mice were treated with clozapine (60 mg/kg/day; n = 20/group), risperidone (3 mg/kg/day; n = 5/group), quetiapine (60 mg/kg/day; n = 10/group), olanzapine (3 mg/kg/day; n = 5/group), or vehicle control commencing one day prior to immunization and were scored daily. (a–d) Shown are the means and SEM of AUC values from individual mice. *p < 0.05 and ****p < 0.0001 compared to vehicle control by Mann–Whitney test. (e, f) Clozapine concentrations were determined in plasma by mass spectrometry and % weight change at 31 days post-immunization. Shown are the means and SEM of values from individual mice combined from four independent experiments (n/group as indicated). *p < 0.05, **p < 0.01, and ****p < 0.0001 by 1-way ANOVA with Tukey’s multiple comparison test and ^##p < 0.01 by unpaired Student’s t-test.